Modulation Of LDL Oxidation By 7,8-Dihydroneopterin
J. Greilberger, K. Oettl, G. Cvirn, G. Reibnegger, G. Juergens
Published 2004 · Medicine, Chemistry
Download PDFAnalyze on Scholarcy
Human macrophages stimulated with interferon-γ generate neopterin and 7,8-dihydroneopterin which interfere with reactive species involved in LDL oxidation. While neopterin was found to have pro-oxidative effects on copper-mediated LDL oxidation, the influence of 7,8-dihydroneopterin is more complex. This study provides detailed information that 7,8-dihydroneopterin reveals both pro-oxidative and anti-oxidative effects on copper mediated LDL oxidation. 7,8-dihydroneopterin inhibited the oxidation of native LDL effectively monitored by (i) formation of conjugated dienes, (ii) relative electrophoretic mobility (EM) and (iii) specific oxidized epitopes. Using minimally oxidized LDL (mi-LDL) or moderately oxidized LDL (mo-LDL) 7,8-dihydroneopterin changed its antioxidative behavior to a strongly pro-oxidative. Incubation of 7,8-dihydroneopterin with native LDL, mi-LDL or mo-LDL in the absence of copper ions showed that formation of conjugated dienes was more increased in mo-LDL than in mi-LDL while no diene formation was observed with native LDL. We suggest that 7,8-dihydroneopterin is a modulator for LDL oxidation in the presence of copper ions depending on the “oxidative status” of this lipoprotein.
This paper references
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application.
H. Wachter (1989)
Detection of new epitopes formed upon oxidation of low-density lipoprotein, lipoprotein (a) and very-low-density lipoprotein. Use of an antiserum against 4-hydroxynonenal-modified low-density lipoprotein.
G. Juergens (1990)
7,8 Dihydroneopterin inhibits low density lipoprotein oxidation in vitro. Evidence that this macrophage secreted pteridine is an anti-oxidant.
S. Gieseg (1995)
Oxidized Lipoproteins and Atherosclerosis
G. M. Chisholm (1996)
A spectrophotometric assay for LPO in serum lipoproteins using a commercially available reagent
M. el-Saadani (1989)
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics.
J. Berliner (1995)
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
J. Fahey (1990)
POSTTRANSPLANT NEOPTERIN EXCRETION IN RENAL ALLOGRAFT RECIPIENTS—A RELIABLE DIAGNOSTIC AID FOR ACUTE REJECTION AND A PREDICTIVE MARKER OF LONG‐TERM GRAFT SURVIVAL
G. Reibnegger (1991)
The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies.
J. Witztum (1997)
LDL- is a lipid hydroperoxide-enriched circulating lipoprotein.
A. Sevanian (1997)
Serum soluble markers of immune J. GREILBERGER et al. 16 activation and disease activity in systemic lupus erythematosus”, Lupus
M. Y. Samsonov (1995)
Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin.
M. Cathcart (1989)
Role of endogenous ceruloplasmin in low density lipoprotein oxidation by human U937 monocytic cells.
E. Ehrenwald (1996)
Neopterin and 7,8-Dihydroneopterin Interfere With Low Density Lipoprotein Oxidation Mediated by Peroxynitrite and/or Copper
Inga Herpfer (2002)
The role of lipid peroxidation and antioxidants in oxidative modification of LDL.
H. Esterbauer (1992)
The Oxidation of lipoproteins by monocytesmacrophages
G. M. Chisholm (1999)
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection.
D. Fuchs (1988)
The Oxidation of Lipoproteins by Monocytes-Macrophages
G. Chisolm (1999)
A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent.
M. el-Saadani (1989)
Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus
M. Samsonov (1995)
Low Density Lipoprotein Oxidation and Its Pathobiological Significance*
D. Steinberg (1997)
Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease.
G. Juergens (1995)
Presence of aldehydic epitopes on a minor low-density lipoprotein fraction.
J. Greilberger (1999)
Human ceruloplasmin. Tissue-specific expression of transcripts produced by alternative splicing.
F. Yang (1990)
Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis.
J. Heinecke (1998)
Neopterin and prognosis in patients with adenocarcinoma of the colon.
G. Weiss (1993)
Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant.
C. Mukhopadhyay (1998)
Cell-mediated oxidation of LDL: comparison of different cell types of the atherosclerotic lesion.
K. Mueller (1998)
Formation of oxygen radicals in solutions of 7,8-dihydroneopterin.
K. Oettl (1999)
Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity.
K. Oettl (2001)
Induction of ceruloplasmin gene expression in rat lung during inflammation and hyperoxia.
R. Fleming (1991)
Interactions of 7,8-dihydroneopterin with copper stability and radical formation (abstract)
K. Oettl (2001)
Collagenous macrophage scavenger receptors
T. Kodama (1996)
7,8-dihydroneopterin and free radicals—a short overview of a fascinating story (abstract)
G. Reibnegger (2001)
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma
C. Huber (1984)
Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal.
G. Juergens (1986)
Cell-mediated reduction of protein and peptide hydroperoxides to reactive free radicals.
H. Headlam (2003)
Biochemical, structural, and functional properties of oxidized low-density lipoprotein.
H. Esterbauer (1990)
This paper is referenced by
Interference of 7,8-dihydroneopterin with peroxynitrite-mediated reactions.
K. Oettl (2004)
Elevated Serum Gamma-Glutamyltransferase (GGT) Activity and the Development of Chronic Kidney Disease (CKD) in Cigarette Smokers
Yuka Noborisaka (2013)
Macrophage mediated protein hydroperoxide formation and lipid oxidation in low density lipoprotein are inhibited by the inflammation marker 7,8-dihydroneopterin.
Carole A Firth (2008)
Nutrition and metabolism Intentional weight loss, blood lipids and coronary morbidity and mortality Review: Intentional weight loss, blood lipids and coronary morbidity and mortality (pp. 5–9)
Inflammatory sites as a source of plasma neopterin: measurement of high levels of neopterin and markers of oxidative stress in pus drained from human abscesses.
Carole A Firth (2008)
Oxidant production, oxLDL uptake, and CD36 levels in human monocyte–derived macrophages are downregulated by the macrophage-generated antioxidant 7,8-dihydroneopterin.
S. Gieseg (2010)
Synthesis, Tautomerism, and Antiradical Activity of Novel Pteridinetrione Derivatives
M. S. Kazunin (2018)
Interferons as Essential Modulators of Atherosclerosis.
Marieke C. S. Boshuizen (2015)
Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8‐dihydroneopterin synthesis
S. Gieseg (2008)
Lysosomal oxidation of Low Density Lipoproteins
F. Ahmad (2017)
A model of complex plaque formation: 7,8-Dihydroneopterin protects human monocyte-derived macrophages from oxidised low density lipoprotein-induced death
Z. Amit (2008)
Mechanisms of 7,8-dihydroneopterin protection of macrophages from cytotoxicity
Anastasia A Shchepetkina (2013)
Cytokines in atherosclerosis: an intricate balance
M. Boshuizen (2016)
Antioxidants, inflammation and cardiovascular disease.
H. Mangge (2014)
Gamma interferon: a central mediator in atherosclerosis
M. L. A. Leon (2005)
Evaluation of serum neopterin, high-sensitivity C-reactive protein and thiobarbituric acid reactive substances in Egyptian patients with acute coronary syndromes.
M. Ragab (2005)
7,8-Dihydroneopterin-mediated protection of low density lipoprotein, but not human macrophages, from oxidative stress
Carole A Firth (2006)